Edition:
United States

Peregrine Pharmaceuticals Inc (PPHM.O)

PPHM.O on Consolidated Issue listed on NASDAQ Capital Market

3.85USD
17 Oct 2017
Change (% chg)

$-0.10 (-2.53%)
Prev Close
$3.95
Open
$3.99
Day's High
$4.08
Day's Low
$3.82
Volume
424,993
Avg. Vol
264,525
52-wk High
$5.78
52-wk Low
$1.97

Latest Key Developments (Source: Significant Developments)

Ronin Trading, SW Investment Management nominate James Egan to Peregrine Pharmaceuticals Board
Tuesday, 10 Oct 2017 12:59pm EDT 

Oct 10 (Reuters) - Ronin Trading, LLC and SW Investment Management LLC::Ronin Trading and SW Investment Management announce additional nomination to Board of Peregrine Pharmaceuticals.Ronin Trading and SW Investment Management - ‍nomination of James (Jamie) J. Egan, for election to Peregrine's Board at co's 2017 annual meeting.‍Ronin Trading and SW Investment Management say collectively have beneficial ownership of about 8.9% of Peregrine's outstanding shares of common stock​.  Full Article

Peregrine Pharma appoints Roger Lias as Avid Bioservices president
Monday, 11 Sep 2017 08:05am EDT 

Sept 11 (Reuters) - Peregrine Pharmaceuticals Inc ::Peregrine Pharmaceuticals announces appointment of Roger J. Lias, PH.D. as president of Avid Bioservices.Peregrine - ‍Steven King will step down from role as president of Avid on Sept 25 and remain as president and chief executive officer of Peregrine​.  Full Article

Peregrine announces measures to reduce costs, facilitate profitability and strengthen its operations
Friday, 11 Aug 2017 08:30am EDT 

Aug 11 (Reuters) - Peregrine Pharmaceuticals Inc :Peregrine announces measures to reduce costs, facilitate profitability and strengthen its operations.Says ‍anticipated annual cost savings of over $7 million​.Peregrine Pharmaceuticals ‍reduced its overall workforce by 60 employees (or 20%) as part of its series of planned strategic actions to reduce costs​.Peregrine Pharmaceuticals Inc - ‍Company expects more than $7 million in reduced annualized operating expenses beginning in fiscal year 2019​.Peregrine Pharmaceuticals Inc - ‍As part of cost saving initiatives, company reduced Peregrine's research and development personnel by 50% to 11 employees​.Peregrine Pharm - ‍Charge to earnings for personnel reductions will be between $1.1 million and $1.7 million, which is expected to be incurred during Q2 2018​.Peregrine Pharmaceuticals Inc - ‍Expects workforce reductions to result in a net cost savings of between $3.7 million and $4.3 million in fiscal year 2018​.Peregrine Pharmaceuticals - ‍Reduction in workforce part of planned actions while co pursues strategic options for its research and development assets​.Peregrine Pharmaceuticals Inc - ‍Expects workforce reductions to result in over $7 million in reduced annualized operating expenses beginning in 2019​.Peregrine - ‍Personnel supporting avid bioservices CDMO business, was reduced by 20 percent to 184 employees to align operations with reduction in forecasted revenues​.  Full Article

Peregrine ‍says "to evaluate strategic options for advancing research and development business​"
Monday, 31 Jul 2017 08:30am EDT 

July 31 (Reuters) - Peregrine Pharmaceuticals Inc :Peregrine provides strategic update.Peregrine Pharmaceuticals Inc - ‍continues to evaluate strategic options for advancing research and development business​.Peregrine Pharmaceuticals Inc - ‍plans to expand board of directors to add CDMO and biologics industry expertise​.Peregrine Pharmaceuticals Inc - ‍intends to increase size of its board of directors from four to up to seven members​.Peregrine Pharmaceuticals Inc - ‍plans to initiate a search for a president to lead its wholly-owned CDMO subsidiary, Avid Bioservices Inc​.  Full Article

Peregrine Pharmaceuticals Q4 revenue $17.9 million
Friday, 14 Jul 2017 04:14pm EDT 

July 14 (Reuters) - Peregrine Pharmaceuticals Inc :Peregrine Pharmaceuticals reports financial results for quarter and fiscal year ended April 30, 2017 and recent developments.Q4 loss per share $0.16.Q4 revenue $17.9 million.  Full Article

Ronin Trading and SW Investment Management issue letter to stockholders of Peregrine Pharmaceuticals
Thursday, 13 Jul 2017 08:55am EDT 

July 13 (Reuters) - Peregrine Pharmaceuticals Inc ::Ronin Trading and SW Investment Management issue letter to stockholders of Peregrine Pharmaceuticals.‍ronin Trading and SW Investment Management say they collectively have beneficial ownership of about 8.8 percent of Peregrine Pharmaceuticals​ stock.Ronin Trading and SW Investment - in letter Ronin announced it has formally nominated three independent candidates for election to Peregrine‍'s board​.  Full Article

Peregrine says common stock to trade on July 10 on a split-adjusted basis
Friday, 7 Jul 2017 10:25am EDT 

July 7 (Reuters) - Peregrine Pharmaceuticals Inc :Peregrine pharmaceuticals announces reverse stock split.Peregrine pharmaceuticals -previously approved 1-for-7 reverse split of its outstanding shares of common stock will take effect on july 7, 2017.Peregrine pharmaceuticals -common stock will open for trading on nasdaq capital market on july 10, on a split-adjusted basis.  Full Article

Ronin Capital LLC reports 5.8 pct stake in Peregrine Pharmaceuticals
Monday, 17 Apr 2017 02:30pm EDT 

April 17 (Reuters) - Peregrine Pharmaceuticals Inc :Ronin Capital LLC reports 5.8 percent stake in Peregrine Pharmaceuticals Inc as of April 6 - sec filing.  Full Article

Peregrine Pharmaceuticals Q3 loss per share $0.04
Monday, 13 Mar 2017 04:37pm EDT 

Peregrine Pharmaceuticals Inc : Sees FY 2017 revenue from avid bioservices business of $60 million-$65 million . Increasing FY Avid Bioservices business manufacturing revenue outlook to $60 - $65 million from $50 - $55 million . Peregrine pharmaceuticals reports financial results for the third quarter of fiscal year 2017 and recent developments .Q3 loss per share $0.04.  Full Article

Peregrine Pharmaceuticals Q4 loss per share $0.05
Thursday, 14 Jul 2016 04:05pm EDT 

Peregrine Pharmaceuticals Inc : Peregrine pharmaceuticals reports financial results for quarter and fiscal year ended april 30, 2016 and recent developments . Q4 loss per share $0.05 . Q4 revenue $18.78 million versus i/b/e/s view $15.8 million . Q4 earnings per share view $-0.03 -- Thomson Reuters I/B/E/S . Peregrine pharmaceuticals inc says analysis of data from sunrise phase iii trial ongoing with new clinical trials expected to commence late 2016 to early 2017 .Says Growing Biomanufacturing Demand Prompts Plans For Third Manufacturing Facility Expected To Be Commissioned By Mid 2017.  Full Article